Tirzepatide
27610
Phase 3 small_molecule active
Quick answer
Tirzepatide for Metabolic Dysfunction-Associated Steatotic Liver Disease is a Phase 3 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly and Company
- Indication
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active